4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Atrial Fibrillation by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 726 ongoing clinical trials involving Atrial Fibrillation
Of the 726 trials,271 trials are in Phase IV
Furthermore, 241 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Atrial Fibrillation by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Atrial Fibrillation, a cardiovascular disorder. The highest number of ongoing clinical trials involving Atrial Fibrillation is conducted in the Asia-Pacific region. North America, and Europe are among some of the other prominent regions involved in Atrial Fibrillation-related drug trials.

Yonsei University: The leading ongoing Atrial Fibrillation related clinical trial sponsor

Yonsei University is the top sponsor for Atrial Fibrillation-related ongoing clinical trials.

Bayer AG, Population Health Research Institute, Severance Hospital, Yonsei University Health System, and Daiichi Sankyo Co Ltd are a few other notable clinical trial sponsors involving Atrial Fibrillation. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Atrial Fibrillation

Clopidogrel bisulfate (Plavix, Iscover, Sanik, Lopigrel, Clopidogrel), Metoprolol succinate (Toprol-XL, Zarmine, Beloken, Seloken, Metoprodur, Selozok, Betaloc CR, BetalocZok, Agoloc, BelokZok), and Dronedarone Hydrochloride (Multaq) are among the key marketed drugs involving Atrial Fibrillation.

Clopidogrel bisulfate (Plavix, Iscover, Sanik, Lopigrel, Clopidogrel) is a thienopyridine antiplatelet agent. Clopidogrel bisulfate functions via P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12) Antagonist mechanism of action. It is formulated as tablets, coated tablets and film coated tablets for oral route of administration. It is marketed for the treatment of Atrial Fibrillation and several other indications including Angina (Angina Pectoris), Thrombosis, Myocardial Infarction, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Atherosclerosis, Stroke, Unstable Angina, Ischemic Stroke, Acute Coronary Syndrome, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Ischemia, Stable Angina, Thromboembolic Disease, Thromboembolism, and Transient Ischemic Attack. Clopidogrel bisulfate was first approved in 1997 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Sanofi and several other companies includingBristol-Myers Squibb Co, and Nichi-Iko Pharmaceutical Co Ltd.

Metoprolol succinate (Toprol-XL, Zarmine, Beloken, Seloken, Metoprodur, Selozok, Betaloc CR, BetalocZok, Agoloc, BelokZok,) belongs to anti-hypertensive, cardiovascular, anti-anginal agents class. Metoprolol succinate function via Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor ADRB1) Antagonist mechanism of action. It is formulated as extended-release tablets and film coated tablets for oral route of administration. It is marketed for the treatment of Atrial Fibrillation and several other indications including Angina (Angina Pectoris), Arrhythmias, Cardiovascular Risk Factors, Hypertension, Myocardial Infarction, Migraine, Tachycardia (Tachyarrhythmias), Congestive Heart Failure (Heart Failure), Left Ventricular Dysfunction, and Chronic Heart Failure. Metoprolol succinate was first approved in 1981 and is marketed globally including the US, Australia, France, Germany, China and Japan by AstraZeneca plc and several other companies including Toprol Acquisition LLC, Lannett Co Inc, and Recordati AG.